Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Earnings for Arrowhead Pharmaceuticals, Inc. (ARWR)
Earnings in 2024 (TTM): $-602,260,000
According to Arrowhead Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-602,260,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Arrowhead Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2024 | $-602,260,000 | $-599,493,000 |
| 2023 | $-206,491,000 | $-205,275,000 |
| 2022 | $-172,709,000 | $-176,494,000 |
| 2021 | $-140,846,000 | $-140,848,000 |
| 2020 | $-84,550,826 | $-84,553,226 |
| 2019 | $68.15 M | $67.97 M |
| 2018 | $-54,448,078 | $-54,450,478 |
| 2017 | $-34,377,895 | $-34,380,295 |
| 2016 | $-81,720,602 | $-81,723,002 |
| 2015 | $-91,938,482 | $-91,940,882 |
| 2014 | $-58,720,112 | $-58,630,190 |
| 2013 | $-31,703,079 | $-31,143,289 |
| 2012 | $-22,110,643 | $-21,125,928 |
| 2011 | $-8,785,008 | $-3,128,885 |
| 2010 | $-7,336,355 | $-5,774,048 |
| 2009 | $-19,157,561 | $-19,308,392 |
| 2008 | $-35,117,310 | $-27,089,030 |
| 2007 | $-37,948,843 | $-29,931,118 |
| 2006 | $-21,924,006 | $-18,997,209 |
| 2005 | $-6,987,885 | $-6,624,824 |
| 2004 | $-2,496,142 | $-2,496,942 |
| 2003 | $-94,438 | $-95,238 |
| 2002 | $-246,207 | $-246,207 |
| 2001 | $-185,821 | $-185,821 |
| 2000 | $-137,553 | $-137,553 |
| 1999 | $-368,459 | $593 K |
| 1998 | $-10,535 | $-51,620 |
| 1997 | $-854,535 | $-854,535 |